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ABSTRACT
PURPOSES: Osteoprotegerin (OPG) is an inhibitor of osteoclastogenesis, but is produced from vasculature, 
too. There is recent evidence of increased circulating OPG levels in patients with diabetes as well as in pa-
tients with coronary artery disease (CAD). Up to date, there are no sufficient data about OPG concentrations 
in newly-diagnosed type 2 diabetes mellitus (nT2DM) patients. The aim of our study was to determine the 
serum OPG levels in males with nT2DM without known concomitant CAD and to investigate the association 
of OPG with intima-media thickness (IMT) of common carotid arteries and glucometabolic parameters.
MATERIAL AND METHODS: Serum OPG levels were measured in 31 nT2DM males and 15 age- and body 
mass index (BMI)-matched non-diabetic male subjects. IMT of common carotid arteries was measured by a 
7,5-MHz B-mode ultrasonography. OPG was estimated by ELISA (BioMedica) in pmol/L.
RESULTS: OPG was significantly higher in nT2DM patients when compared to controls (4,59±0,28 versus 
3,20±0,30 pmol/L; p=0,004). In the whole group of subjects, there was a positive correlation of OPG levels 
with glucose parameters: fasting plasma glucose (FPG) (r=0,38; p=0,01), 2-hour post-challenge glucose 
(r=0,45; p=0,003) and HbA1c (r=0,46; p=0,002). Moreover, OPG correlated significantly with carotid IMT 
(Pr 0,40; p=0,01).
CONCLUSION:  Serum OPG is significantly elevated in nT2DM males without known CAD compared to 
non-diabetic controls. OPG levels show associations not only with some glucose indices but also with IMT, 
one of the earliest atherosclerotic markers. Probably, these glucose indices and this vascular parameter are 
involved in OPG regulation. We could suggest that OPG rises early in the evolution of diabetic disorders. 
However, further investigations are needed.
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INTRODUCTION
Osteoprotegerin (OPG) is an inhibitor of 
osteoclastogenesis, but is produced from vasculature, 
too. OPG is a secreted member of the tumour necro-
sis factor (TNF) receptor superfamily and acts as a 
strong anti-resorptive factor through binding and 
neutralizing the receptor activator for NF-kB ligand 
(RANKL) (15). OPG is also present in the arterial 
wall and elevated plasma OPG is suggested to reflect 
the increased OPG content in atherosclerotic arterial 
66  Scripta Scientifica Medica, vol. 45, No 3, 2013, pp. 65-68
Copyright © Medical University of Varna
High osteoprotegerin serum levels in newly-diagnosed type 2 diabetic males without known coronary artery disease
tissues (11). OPG is a promising biomarker of athero-
sclerosis (10). There is recent evidence of increased 
circulating OPG levels in patients with diabetes 
as well as in patients with coronary artery disease 
(CAD). OPG is associated with CAD severity and 
cardiovascular events independently of convention-
al risk factors (6,7). Moreover, the higher OPG level 
is an independent predictive factor in patients with 
intermediate coronary lesions (16). In type 2 diabe-
tes mellitus (T2DM) patients, elevated serum OPG 
appears to be a powerful and independent predictor 
for cardiovascular morbidity and mortality during 
17 years of follow-up (13). Notably, plasma OPG lev-
els predict cardiovascular events in uncomplicated 
T2DM patients (2), too. Recent studies report that in-
tima-media thickness (IMT) of common carotid ar-
tery, a well-known early atherosclerotic marker, is 
positively correlated to circulating OPG levels in dia-
betic patients (5,12). OPG is associated with the gly-
cemic control, endothelial dysfunction and cardio-
vascular risk in T2DM (1,4). Up to date, there are no 
sufficient data about OPG concentrations in newly-
diagnosed T2DM (nT2DM) patients. 
The aim of our study was to determine the se-
rum OPG levels in males with nT2DM without 
known concomitant CAD and to investigate the as-
sociation of OPG with IMT and glucometabolic 
parameters.
MATERIAL AND METHODS
Serum OPG levels were measured in 31 nT2DM 
males and 15 age- and body mass index (BMI)-
matched non-diabetic male subjects (controls). The 
patients with nT2DM were screen-detected by oral 
glucose tolerance test (OGTT) among risk individ-
uals and had no history of CAD. IMT of common 
carotid arteries (CCAs) was measured by a 7,5-MHz 
B-mode ultrasonography (Fokuda) prior to the de-
termination of OPG and glucometabolic parame-
ters. Three manual measurements of each CCA were 
performed over 1-cm span ending 1 cm proximal-
ly to the transition between the CCA and bulb re-
gion. The distance between lumen-intima borderline 
and media-adventitia one on the far wall was mea-
sured. Mean IMT was calculated from the measure-
ments on both sides. OPG was estimated by ELISA 
(BioMedica) in pmol/L according to the protocol of 
manufacture. Data regarding risk factors, medical 
history and concomitant medications were collected. 
Systolic and diastolic blood pressure was measured 
three times on each arm. Anthropometric measure-
ments included height, weight, waist circumference 
and BMI calculation. Venous plasma was centrifuged 
immediately after blood collection and glucose con-
centrations were determined by hexokinase meth-
od. Fasting plasma glucose (FPG) and 2-hour post-
challenge glucose were measured. Glycated hemo-
globin (HbA1c) was measured by immunoassay for 
the quantitative determination of percentage hemo-
globin A1c in whole blood samples on the AxSYM 
System (Abbott, USA). Serum levels of triglycerides 
(TG), total cholesterol (TC), LDL-cholesterol (LDL-
C) and HDL-cholesterol (HDL-C) were determined 
enzymatically. Fasting serum insulin was assessed by 
microparticle enzyme immunoassay (Abbott, USA). 
Insulin resistance was calculated using homeosta-
sis model assessment of insulin resistance (HOMA-
IR). Statistical analysis was done using GraphPad 
Prism version 5 and included calculation of corre-
lations. Data are expressed as means±SD. Value of 
p<0,05 was considered statistically significant. The 
study was approved by the Ethical Commission of 
the Medical University of Varna. 
RESULTS
Table 1 shows the baseline characteristics of the 
study participants. 
OPG is significantly higher in nT2DM patients 
when compared to controls (4,59±0,28 versus 
3,20±0,30 pmol/L; p=0,004) (Fig. 1). In the whole 
group of subjects, there is a positive correlation of 
OPG levels with glucose parameters: FPG (r=0,38; 
p=0,01), 120-min. post-OGTT glucose (r=0,45; 
p=0,003) and HbA1c (r=0,46; p=0,002). Moreover, 
OPG correlates significantly with carotid IMT (Pr 
0,40; p=0,01).
There are no correlations between OPG and 
fasting insulin, HOMA-IR, systolic and diastolic 
blood pressure, BMI, or waist circumference. 
When lipid profile parameters are concerned, OPG 
correlates positively with HDL-C (r=0,43; p=0,049) 
in nT2DM patients only.
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DISCUSSION
We established higher serum OPG levels in nT-
2DM patients without any history of CAD than in 
healthy controls. Although several studies indicate 
that serum OPG is significantly increased in T2DM 
(8,9,14), scanty data are available about serum OPG, 
especially in nT2DM patients without known CAD. 
We proved positive correlations between OPG and 
several parameters of glucose metabolism such as 
FPG, 2-h post-challenge glucose and A1c. That is why 
we could speculate that they may be involved in OPG 
regulation. An elevated serum OPG was demonstrat-
ed in recently diagnosed T2DM patients (within 2 
years) as well as soon after diabetic induction in ani-
mal models (14). A positive correlation between OPG 
and glycemic levels was established, too (14).
On the other hand, we revealed a positive 
association of OPG with IMT, a well-known early 
atherosclerotic marker. In the diabetic population, 
OPG was associated with silent CAD (3) and predict-
ed cardiovascular events in uncomplicated T2DM 
patients (2). Although the exact role of OPG in vas-
culature is unknown, the paradoxical OPG increase 
has been interpreted as a counter-regulatory protec-
tive response to atherosclerosis. 
CONCLUSION
Serum OPG is significantly elevated in nT-
2DM males without known CAD compared to non-
diabetic controls. OPG levels show associations not 
only with some glucose indices but also with IMT, 
one of the earliest atherosclerotic markers. Probably, 
these glucose indices and this vascular parameter are 
involved in OPG regulation. We could suggest that 
Table 1. Characteristics of study participants
nT2DM (n=31) Controls (n=15)  p
age (years) 53,2±7,8 53,8±7,1 0,8
BMI (kg/m2) 33,0±3,9 31,0±3,0 0,1
waist circumference (cm) 111,5±10,9 107,0±9,0 0,2
FPG (mmol/L) 10,7±3,1 5,8±0,5 <0,0001
2-h plasma glucose (mmol/L) 14,96±5,43 5,68±1,45 <0,0001
HbA1c (%) 7,77±1,73 5,43±0,40 <0,0001
TC (mmol/L) 6,14±1,59 6,82±1,50 0,3
TG (mmol/L) 2,88±2,57 2,45±1,06 0,6
LDL-C (mmol/L) 3,06±1,01 4,60±1,22 0,002
HDL-C (mmol/L) 1,13±0,29 1,12±0,24 0,9
IMT (mm) 0,7±0,1 0,6±0,1 0,02
fasting serum insilin (µU/ml) 15,6±11,1 11,0±5,1 0,2
Data are expressed as mean±SD
Fig. 1. Mean OPG serum levels in subjects with nT2DM 
and controls
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OPG rises early in the evolution of diabetic disorders. 
However, further investigations are needed.
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